Role of ecDNA in Cancer Progression

Cancer genomes are often described as unstable, rearranged, and highly adaptable. In many tumors, however, some of the most consequential genetic changes are not embedded within chromosomes at all. Instead, cancer-driving genomic regions can exist as circular DNA molecules outside the chromosomes. These structures are known as extrachromosomal DNA, or ecDNA.

ecDNA has gained increasing attention because it provides cancer cells with a flexible route to amplify oncogenes, alter transcriptional regulation, and generate intratumoral heterogeneity. Rather than following the stable inheritance patterns of chromosomal DNA, ecDNA can be unevenly distributed during cell division. This allows tumor cell populations to change rapidly, particularly under selective pressures such as therapy.

Large-scale genomic analyses have shown that ecDNA is not a rare curiosity. Bailey et al. reported ecDNA in 17.1% of tumor samples across 14,778 patients and 39 tumor types, with associations to tumor stage, metastasis, treatment exposure, and shorter overall survival.

The therapeutic implications are especially relevant. ecDNA-positive cancers often carry highly amplified and highly transcribed oncogenes, which can create replication stress and transcription–replication conflicts. Recent work by Tang et al. suggests that this stress may be exploitable through CHK1 inhibition, opening the possibility of therapeutic strategies directed specifically at ecDNA-positive tumors.

What is ecDNA?

Extrachromosomal DNA describes circular DNA molecules that are located outside the normal chromosomal genome. In cancer, ecDNAs are often large, chromatinized, nuclear DNA structures that can contain complete genes as well as regulatory elements such as enhancers and promoters.

A defining feature of ecDNA is that it lacks a centromere. Centromeres are required for the accurate distribution of chromosomes during mitosis. Because ecDNA does not contain centromeres, it is not inherited with the same precision as chromosomal DNA. Instead, ecDNA molecules can segregate unevenly between daughter cells. One cell may inherit many copies of an oncogene-bearing circle, while another may receive fewer copies (fig.1).

This irregular inheritance gives tumors a flexible genetic system outside the usual chromosomal framework. A chromosomal amplification is relatively fixed once established. An ecDNA amplification is more dynamic. Its copy number can vary between cells, it can cluster with other ecDNA molecules, and it can be selected for or against depending on the tumor environment.

How ecDNA Forms

ecDNA formation is closely linked to genomic instability. The process is not directed or intentional. Instead, chromosomal DNA can break, rearrange, and circularize during error-prone repair or catastrophic genomic events. If the resulting circular DNA contains genes or regulatory elements that provide a growth or survival advantage, cells carrying those ecDNAs may expand during tumor evolution.

Several mechanisms are thought to contribute to ecDNA formation. One important route is Chromothripsis. Another proposed mechanism involves breakage–fusion–bridge cycles. These cycles can occur when chromosomes lose protective telomere function or undergo breakage. Repeated fusion and breakage events can generate focal amplifications and rearranged DNA fragments, some of which may contribute to extrachromosomal circular DNA formation.

DNA repair defects may also influence ecDNA biology. Tumors with impaired genome maintenance can accumulate rearrangements that increase the probability of circular DNA formation. Bailey et al. also linked ecDNA to mutational processes associated with environmental exposure and DNA repair deficiency, including tobacco-related signatures and homologous recombination repair deficiency.

More recent work by Sankar et al. adds another layer to ecDNA persistence. The authors identified retention elements, CpG-rich promoter-associated sequences that can tether episomal DNA to mitotic chromosomes. These elements increase the likelihood that circular DNA molecules are transmitted to daughter cells. This suggests that ecDNA structure is shaped not only by oncogene content, but also by features that help ecDNA persist across cell generations.

How ecDNA Amplifies Oncogene Activity

The central biological impact of ecDNA is not limited to gene copy number. ecDNA can increase oncogene dosage, change the regulatory environment around those genes, and create cell-to-cell variation in oncogene expression. These effects are interconnected and help explain why ecDNA-positive tumors are often highly adaptable.

Genome instability can randomly generate circular DNA fragments. Some of these fragments may contain oncogenes or regulatory sequences that improve tumor cell fitness. Cells carrying advantageous ecDNA configurations can then be selected during tumor evolution. In this way, ecDNA acts as a substrate for selection rather than as a purposeful strategy of the cancer cell.

Bailey et al. reported that ecDNAs frequently carry genes involved in major cancer pathways, including RTK–RAS signaling, TP53 regulation, and cell-cycle control. Relevant examples include EGFR, ERBB2, FGFR1, FGFR2, PDGFRA, MYC, MDM2, CCND1, and CDK4. When these genes are present on ecDNA, they may occur at high copy number and contribute to increased pathway activity.

The circular structure of ecDNA also creates opportunities for altered gene regulation. ecDNAs can contain enhancers, promoters, and other regulatory elements that interact with oncogenes on the same circle. In addition, ecDNAs often cluster into shared nuclear hubs. This hub-based organization helps explain why ecDNA can drive particularly strong oncogene expression.

Because ecDNA lacks centromeres, its inheritance during mitosis is uneven. Daughter cells may receive different numbers and combinations of ecDNA molecules. This produces intratumoral heterogeneity, with individual cells differing in oncogene dosage, regulatory interactions, and pathway activation. Under therapy or other selective pressures, subclones with favorable ecDNA compositions may expand.

ecDNA may also affect tumor–immune interactions. Bailey et al. reported that ecDNAs can amplify immunomodulatory and inflammatory genes and that ecDNA carrying immunomodulatory genes was associated with reduced tumor T-cell infiltration. This links ecDNA not only to genome instability and proliferative signaling, but also to mechanisms relevant to immune evasion.

Clinical Implications of ecDNA in Cancer

The presence of ecDNA has important clinical implications. Bailey et al. associated ecDNA detection with more advanced tumor stage, metastatic disease, prior treatment exposure, and shorter overall survival. This supports the view that ecDNA is a clinically relevant feature of aggressive cancer biology.

From a diagnostic perspective, ecDNA status may become useful for tumor stratification and biomarker development. Current approaches include whole-genome sequencing, computational reconstruction of focal amplifications, and cytogenetic methods such as fluorescence in situ hybridization. In selected tumor settings, probes against genes such as MDM2, CDK4, PDGFRA, and MYC may help visualize ecDNA-associated amplifications.

At the same time, ecDNA biology may expose new therapeutic vulnerabilities. ecDNA-positive cells often carry highly amplified and highly transcribed oncogenes. This can increase transcription–replication conflict, replication stress, and DNA damage. To tolerate this stress, these cells may become more dependent on checkpoint and DNA damage response pathways.

Tang et al. showed that ecDNA-containing tumor cells display increased transcription–replication conflict and activation of the S-phase checkpoint kinase CHK1. Genetic or pharmacological CHK1 inhibition caused preferential death of ecDNA-containing tumor cells in experimental models. In a gastric cancer model with FGFR2 amplified on ecDNA, the CHK1 inhibitor BBI-2779 suppressed tumor growth and prevented ecDNA-mediated acquired resistance to the FGFR inhibitor infigratinib.

Another emerging therapeutic concept is interference with ecDNA maintenance. Sankar et al. showed that retention elements can promote ecDNA transmission by tethering episomal DNA to mitotic chromosomes. In experimental systems, targeted cytosine methylation disrupted retention activity and contributed to ecDNA loss. Although this remains a preclinical concept, it suggests that future therapies may not only target proteins encoded by ecDNA, but also the mechanisms that allow ecDNA to persist in tumor cell populations.

Together, these findings frame ecDNA as both a clinical risk feature and a therapeutic opportunity. ecDNA can support tumor progression, heterogeneity, and resistance, but its unusual replication, transcriptional, and inheritance patterns may also create dependencies that can be exploited therapeutically.

References